Torsemide is a loop diuretic indicated for the treatment of edema associated with heart failure, renal disease or hepatic disease, among other approved uses. It is available as tablets for oral use. MedsAcross supplies Torsemide for export from India to licensed hospitals, importers and physicians acting for named patients, with the documents each country requires.
Information from the US FDA prescribing information, retrieved 12 November 2026. Not yet medically reviewed.How we review
From the regulator-approved product information. Each section names its source.
Torsemide is a loop diuretic indicated for: the treatment of edema associated with heart failure, renal disease or hepatic disease. the treatment of hypertension, to lower blood pressure. Lowering blood pressure reduces the risk of fatal and nonfatal cardiovascular events, primarily strokes and myocardial infarctions.
Source: US FDA prescribing information
Micropuncture studies in animals have shown that torsemide acts from within the lumen of the thick ascending portion of the loop of Henle, where it inhibits the Na + /K + /2Cl–-carrier system. Clinical pharmacology studies have confirmed this site of action in humans, and effects in other segments of the nephron have not been demonstrated. Diuretic activity thus correlates better with the rate of drug excretion in the urine than with the concentration in the blood. Torsemide increases the urinary excretion of sodium, chloride, and water, but it does not significantly alter glomerular filtration rate, renal plasma flow, or acid-base balance.
Source: US FDA prescribing information
Edema associated with: Heart failure: Initial dose is 10 or 20 mg once daily. Titrate by factors of two, doses above 200 mg have not been studied. Chronic Renal Failure: Initial dose is 20 mg once daily. Hepatic Cirrhosis: Initial dose is 5 or 10 mg once daily. Titrate by factors of two, doses above 40 mg have not been studied. Hypertension: The recommended initial dose is 5 mg once daily. After 4 to 6 weeks, increase to 10 mg once daily, if needed. If 10 mg is insufficient, consider adding another agent.
Source: US FDA prescribing information
Torsemide tablets are contraindicated in patients with known hypersensitivity to torsemide or to povidone. Torsemide tablets are contraindicated in patients who are anuric. Torsemide tablets are contraindicated in patients with hepatic coma. Hypersensitivity to torsemide or povidone, anuria, and hepatic coma.
Source: US FDA prescribing information
Hypotension and worsening renal function: monitor volume status and renal function periodically. Electrolyte and metabolic abnormalities: monitor serum electrolytes and blood glucose periodically. Ototoxicity
Source: US FDA prescribing information
The following risks are discussed in more detail in others sections: Hypotension and Worsening Renal Function Electrolyte and Metabolic Abnormalities Ototoxicity The most common adverse reaction is excessive urination (6.7%).
Source: US FDA prescribing information
Non-steroidal anti-inflammatory drugs (NSAIDs): Reduced diuretic, natriuretic, and antihypertensive effects, risk of renal impairment. CYP2C9: Concomitant use with CYP2C9 inhibitors can decrease torsemide clearance. Torsemide may affect the efficacy and safety of sensitive CYP2C9 substrates or of substrates with a narrow therapeutic range, such as warfarin or phenytoin. Cholestyramine: Decreased exposure of torsemide. Organic anion drugs: may decrease diuretic activity of torsemide. Lithium: Risk of lithium toxicity. Renin-angiotensin inhibitors: Increased risk of hypotension and renal impairment. Radiocontrast agents: Increased risk of renal toxicity. Corticosteroids and ACTH: Increased risk of hypokalemia.
Source: US FDA prescribing information
Storage Store at 20°C to 25°C (68°F to 77°F).
Source: US FDA prescribing information
For healthcare professionals and buyers. This is not medical advice. Treatment decisions belong to the prescriber.
5 presentations of Torsemide, sorted by availability.
| Medicine | Manufacturer | Register | Availability |
|---|---|---|---|
| Torsemide 20 mg tabletOralGeneric name | — | US FDA | Available on request |
| Torsemide 10 mg tabletOralGeneric name | — | US FDA | Available on request |
| Torsemide 100 mg tabletOralGeneric name | — | US FDA | Available on request |
| Torsemide 5 mg tabletOralGeneric name | — | US FDA | Available on request |
| Soaanz 40 mg tabletOral | Sarfez Pharmaceuticals | US FDA | Available on request |
1 brand names across 1 markets.
United States
Approval facts from US FDA, EMA and CDSCO data, and registration status by country where we hold register data.
| Register | Status | Source |
|---|---|---|
| US FDA | First approved 23 August 1993 | Drugs@FDA |
| EU (EMA) | Not recorded | — |
| India (CDSCO) | Not yet confirmed against CDSCO approval lists | — |
| United States | Registered | US FDA (NDC directory, openFDA)Checked 12 November 2026 |
Conditions linked to Torsemide in public data. This is not a list of approved uses, see the clinical information.
Yes, on request. MedsAcross lists 5 presentations of Torsemide and sources them for licensed hospitals, importers and physicians against valid import documents.
The catalogue lists 1 brand names for Torsemide, including Soaanz.
Yes. The US FDA first approved Torsemide on 23 August 1993, according to Drugs@FDA.
No listed presentation of Torsemide is recorded as needing a cold chain. Storage conditions are shown on each presentation page.
Torsemide is classified under ATC code C03CA04 (Torsemide).
Tell us the strength, quantity and destination country. Our team replies with availability, lead time and the import documents needed.